Lentigen Names Invitrogen Alumnus to New Position; ChemGenex Hires New Cancer VP; Micronics Adds a Director; and Others | GenomeWeb
NEW YORK (GenomeWeb News) — Lentigen has named Adam Sachs to the newly created position of president of commercial operations, where he will lead efforts to market the firm’s lentiviral platform, the company said.
 
Sachs comes to Lentigen having spent 15 years in the biotech field, most recently as a molecular biology product development executive at Life Technologies, which is now Invitrogen.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.